Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- FDA approves Alzheimer's drug
- The Federal Drug Administration has approved Aricept to treat people with severe Alzheimer's disease.
- Research articles 2006-10-25
- Siemens and UCLA Researchers Get FDA "Green Light" for Clinical Study of Alzheimer's-Specific Imaging Agent
- Study Will Measure the Safety of One of the First Imaging Biomarkers Designed to Differentiate Alzheimer's Disease from Other Forms of Dementia
- Research articles 2006-12-20
- Applied NeuroSolutions Takes First Step In Commercialization of Diagnostic Alzheimer's Disease Test; Company Begins Process with FDA
- VERNON HILLS, Ill. -- Applied NeuroSolutions, Inc. (OTC BB:APNS) (www.appliedneurosolutions.com) today announced that it has submitted a pre-IDE Investigational Device Exemption application with the FDA, a milestone in the process of commercializing its cerebrospinal fluid CSF diagnostic Alzheimer's disease AD test.
- Research articles 2005-09-08
- Treatment options expand for Alzheimer's disease.(Pharmaceuticals)
- TREATMENT OPTIONS for Alzheimer's disease patients are set to widen, with a Food and Drug Administration FDA advisory committee recently recommending approval for Forest Laboratories Inc.'s Namenda memantine. The drug not only offers a differen TREATMENT OPTIONS for Alzheimer's disease patients are set to...
- Research articles 2003-10-06
- FDA approves Reminyl for Alzheimer's
- * FDA has approved Reminyl galantamine hydrobromide, developed by Janssen Pharmaceutica with Britain's Shire Pharmaceutical Group, for treatment of mild to moderate Alzheimer's disease.
- Research articles 2001-04-01
- Forest Labs gets FDA panel approval for Alzheimer's drug.(News)(Brief Article)
- A FOOD and Drug Administration FDA advisory committee has recommended approval of Forest Laboratories Inc.'s Alzheimer's disease drug Namenda, formerly known as memantine. Although the panel says the effects of the drug are modest, upon final app A FOOD and Drug Administration FDA advisory...
- Research articles 2003-09-29
- Alzheimer's Growth Shows Need for Increased FDA Funding
- To: MEDICAL EDITORSTo: MEDICAL EDITORS
- Research articles 2007-03-21
- UNIVERSITY OF OXFORD, AMERSHAM HEALTHCARE, AND BRISTOL-MYERS SQUIBB SIGN AGREEMENT INVOLVING TEST FOR ALZHEIMER'S DISEASE; New imaging technique could speed detection, help evaluate new treatments, and receive expedited review at FDA
- ARLINGTON HEIGHTS, Ill.--HealthWire--March 29, 1996-- Medi-Physics Inc., Amersham Healthcare announced today a licensing agreement between its UK-based parent, Amersham International plc, Bristol-Myers Squibb Company (NYSE: BMY), and the University of Oxford, one of Britain's premier universities and medical centers. The agreement will likely result in Medi-Physics petitioning the U.S. Food...
- Research articles 1996-03-29
- FDA Approves New Drug to Treat Alzheimer's Disease; Families Should Consult Physicians About Potential Benefits, Risks and Costs
- Health & Medical Writers
- Research articles 2000-04-24
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(Alzheimer's disease drug application with FDA voluntarily withdrawn after Phase III trial)(Government Activity)(Product Development)(Brief Article)
- FOREST Laboratories Inc. has voluntarily withdrawn its new drug application NDA with the Food and Drug Administra-tion FDA to market memantine for moderate-to-severe Alzheimer's disease. Forest expects a refiling and submission of new study dat FOREST Laboratories Inc. has voluntarily withdrawn its new drug...
- Research articles 2002-09-30
- Nymox Scientists Uncover Major New Molecular Clue To Alzheimer's Disease; Nymox Also Plans To File Investigational New Drug Application With FDA For New Alzheimer Drug Candidate.
- MAYWOOD, NEW JERSEY, May 27, 2003 CCNMatthews via COMTEX MAYWOOD, NEW JERSEY, May 27, 2003 CCNMatthews via COMTEX
- Research articles 2003-05-27
- << Previous
- page 1 of 1
- Next >>
